PMID- 16972019
OWN - NLM
STAT- MEDLINE
DCOM- 20070426
LR  - 20181113
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 26
IP  - 3
DP  - 2007 Mar
TI  - Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix 
      metalloproteinase-3 in sera from patients with active untreated adult onset 
      Still's disease.
PG  - 393-400
AB  - To investigate serum levels of soluble Fas (sFas), soluble Fas ligand (sFas-L), 
      and matrix metalloproteinase-3 (MMP-3) in patients with active untreated adult 
      onset Still's disease (AOSD). Serum levels of sFas, sFas-L, and MMP-3 were 
      determined by enzyme-linked immunosorbent assays in 20 patients with active 
      untreated AOSD, 20 patients with active rheumatoid arthritis (RA), and 20 healthy 
      controls. Linear regression was used to evaluate the correlation between clinical 
      activity scores and serum levels of sFas, sFas-L, and MMP-3 in AOSD patients. 
      Significantly higher levels of sFas, sFas-L, and MMP-3 in sera were found in 
      active untreated AOSD patients compared to healthy controls. Serum levels of 
      sFas, sFas-L, and MMP-3 correlated well with clinical activity scores of AOSD 
      patients (r=0.467, 0.694, and 0.798, respectively). There was a significant 
      correlation between CRP values and serum levels of sFas-L as well as MMP-3 
      (r=0.583 and r=0.582, respectively, both p<0.01), and a positive correlation 
      between serum sFas-L levels and serum MMP-3 levels (r=0.726, p<0.001) in AOSD 
      patients. Significantly higher levels of serum sFas-L were found in AOSD patients 
      than in RA patients. Serum levels of sFas, sFas-L, and MMP-3 fluctuated and were 
      found to be parallel to disease activity of AOSD. sFas, sFas-L, and MMP-3, which 
      were significantly elevated in sera of active untreated AOSD patients and 
      paralleled disease activity, may be involved in the pathogenesis of this disease. 
      Further studies are needed to determine the pathophysiologic role of sFas, 
      sFas-L, and MMP-3 in AOSD.
FAU - Chen, Der-Yuan
AU  - Chen DY
AD  - School of Medicine, National Yang-Ming University, Taipei, Taiwan.
FAU - Lan, Joung-Liang
AU  - Lan JL
FAU - Lin, Fang-Ju
AU  - Lin FJ
FAU - Hsieh, Tsu-Yi
AU  - Hsieh TY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060914
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (FAS protein, human)
RN  - 0 (FASLG protein, human)
RN  - 0 (Fas Ligand Protein)
RN  - 0 (fas Receptor)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/blood
MH  - Case-Control Studies
MH  - Fas Ligand Protein/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Still's Disease, Adult-Onset/*blood
MH  - fas Receptor/*blood
EDAT- 2006/09/15 09:00
MHDA- 2007/04/27 09:00
CRDT- 2006/09/15 09:00
PHST- 2005/07/25 00:00 [received]
PHST- 2005/07/27 00:00 [accepted]
PHST- 2006/09/15 09:00 [pubmed]
PHST- 2007/04/27 09:00 [medline]
PHST- 2006/09/15 09:00 [entrez]
AID - 10.1007/s10067-006-0378-z [doi]
PST - ppublish
SO  - Clin Rheumatol. 2007 Mar;26(3):393-400. doi: 10.1007/s10067-006-0378-z. Epub 2006 
      Sep 14.